Genocea Biosciences

Genocea Biosciences is a privately held biotechnology company located in Cambridge, Massachusetts. The company employs 77 individuals and reported $11 million in revenue. Genocea Biosciences is dedicated to developing innovative immunotherapies for cancer patients. At the heart of their approach is the proprietary ATLAS™ platform, a powerful tool that comprehensively analyzes a patient’s T cell responses to potential tumor targets, known as antigens. ATLAS identifies both antigens that stimulate anti-tumor immune responses and inhibitory antigens, called InhibigensTM, which can promote tumor growth. Genocea is currently advancing two key clinical programs. GEN-011, an adoptive T cell therapy targeting neoantigens, is being evaluated in a Phase 1/2a clinical trial. Additionally, they are continuing to monitor patients in the Phase 1/2a clinical trial for GEN-009, a neoantigen vaccine. Genocea also actively explores the potential applications of ATLAS in optimizing antigen selection for therapies across a range of diseases. For more information, please visit Genocea's website at www.genocea.com.